BIO Chairman Sees "Science-Driven" Hamburg As Plus For Regulatory Climate
BIO Board Chairman Stephen Sherwin is looking forward to an improved regulatory environment at FDA for biopharmaceutical companies with the advent of Margaret Hamburg as agency commissioner
You may also be interested in...
FDA Commissioner Margaret Hamburg is including a carrot for industry - a warning letter close-out process - in a multi-stick initiative to strengthen the agency's enforcement program
Rep. Henry Waxman, D-Calif., can perhaps take some comfort in the fact that his defeat on follow-on biologics means his broader health reform legislation may have a greater chance of passage
FDA should explain the why of its important regulatory decisions in consumer-friendly language, according to the Pharmaceutical Research and Manufacturers of America